[Skip to Content]
[Skip to Content Landing]
Views 532
Citations 0
Research Letter
July 2018

Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality

Author Affiliations
  • 1Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Department of Medicine, Medical University of South Carolina, Charleston
JAMA Oncol. 2018;4(7):1006-1008. doi:10.1001/jamaoncol.2018.1263

Based on surrogate markers of benefit, single-arm studies projected that lung cancer screening with computed tomography (CT) would reduce lung cancer mortality by 80%.1 Yet subsequent randomized clinical trials produced findings ranging from no reduction to a 20% reduction.2 We formally evaluated the seemingly misleading surrogates.